Patients with severe eosinophilic asthma who used depemokimab administered every 6 months experienced a 54% reduction in exacerbations over 52 weeks, according to a study presented at the European ...

SAN DIEGO — Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically significant exacerbations, according to a poster abstract ...

Depemokimab is a monoclonal antibody targeting interleukin-5 (IL-5), which plays a crucial role in type 2 inflammation, commonly found in patients with difficult-to-treat asthma and up to 80% of ...

Depemokimab targets interleukin-5 (IL-5), a cytokine involved in type 2 inflammation, which is a common underlying factor in several diseases including asthma and CRSwNP.

Depemokimab-treated patients with uncontrolled asthma symptoms (ACQ ≥1.5) at baseline were shown to have clinically meaningful improvement at Week 52, with 69% classed as responders based on ...

Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, randomized, placebo ...

The British Big Pharma has filed depemokimab for FDA approval in two respiratory indications on the back of new phase 3 data showing the antibody improved disease symptoms and quality of life in ...

Depemokimab is an ultra-long acting biologic with high binding affinity for interleukin-5. This extended half-life allows for twice-yearly (every 6 months) subcutaneous administration.

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials.. The ANCHOR ...

GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise in reducing nasal polyp growth and obstruction. Full results to be ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary for response. Depemokimab reduces exacerbations regardless of baseline ...